| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
867,861 |
| 52
Week Range: |
$187.64 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
19,405 |
84,786 |
513,978 |
| Total Sell Value |
$0 |
$4,136,219 |
$17,259,806 |
$91,955,621 |
| Total People Sold |
0 |
2 |
7 |
9 |
| Total Sell Transactions |
0 |
2 |
25 |
74 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Brothers Life Sciences Lp |
Former 10% Owner |
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$2,147,483,647 |
I/I |
(44,708,503) |
0 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Former 10% Owner |
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$10,661,553 |
D/D |
(46,557) |
0 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2023-12-14 |
4 |
D |
$229.00 |
$21,363,868 |
D/D |
(93,292) |
0 |
|
- |
|
| Romp Charles R |
EVP, Commercial U.S. |
• – – |
2023-12-14 |
4 |
D |
$229.00 |
$7,739,284 |
D/D |
(33,796) |
0 |
|
- |
|
| Love Ted W |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$974,395 |
D/D |
(4,255) |
0 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2023-12-14 |
4 |
D |
$229.00 |
$27,358,859 |
I/I |
(119,471) |
0 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2023-12-14 |
4 |
D |
$229.00 |
$3,406,146 |
D/D |
(14,874) |
0 |
|
- |
|
| Orwin John A |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$6,641,687 |
D/D |
(29,003) |
0 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2023-12-14 |
4 |
D |
$229.00 |
$11,163,292 |
D/D |
(48,748) |
0 |
|
- |
|
| Seth Alpna |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$2,966,237 |
D/D |
(12,953) |
0 |
|
- |
|
| Swain Sandra M |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$178,162 |
D/D |
(778) |
0 |
|
- |
|
| Epstein David R |
CEO |
• • – |
2023-12-14 |
4 |
D |
$229.00 |
$3,757,203 |
D/D |
(16,407) |
0 |
|
- |
|
| Gryska David W |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$11,221,687 |
D/D |
(49,003) |
0 |
|
- |
|
| Welch Daniel G |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$2,456,025 |
I/I |
(10,725) |
0 |
|
- |
|
| Welch Daniel G |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$1,087,750 |
D/D |
(4,750) |
0 |
|
- |
|
| Simonian Nancy A |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$14,370,437 |
D/D |
(62,753) |
0 |
|
- |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-12-14 |
4 |
D |
$229.00 |
$8,779,402 |
D/D |
(38,338) |
0 |
|
- |
|
| Epstein David R |
CEO |
• • – |
2023-11-10 |
4 |
AS |
$213.01 |
$2,262,166 |
D/D |
(10,620) |
136,598 |
|
7% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2023-11-09 |
4 |
AS |
$213.31 |
$1,874,053 |
D/D |
(8,785) |
42,574 |
|
7% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2023-09-21 |
4 |
AS |
$206.50 |
$16,520 |
D/D |
(80) |
128,723 |
|
11% |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2023-09-21 |
4 |
AS |
$206.50 |
$13,216 |
D/D |
(64) |
84,398 |
|
11% |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-09-21 |
4 |
AS |
$206.50 |
$14,662 |
D/D |
(71) |
116,677 |
|
11% |
|
| Romp Charles R |
EVP, Commercial U.S. |
• – – |
2023-09-21 |
4 |
AS |
$206.50 |
$9,293 |
D/D |
(45) |
69,111 |
|
11% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2023-09-21 |
4 |
AS |
$206.50 |
$16,520 |
D/D |
(80) |
51,359 |
|
11% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2023-09-07 |
4 |
AS |
$205.76 |
$1,807,602 |
D/D |
(8,785) |
51,439 |
|
12% |
|
1805 Records found
|
|
Page 1 of 73 |
|
|
